POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES (11.19.2021, 4:50pm CEST, WHO):   India 11,106    Brazil 11,977    United Kingdom 46,858    Russia 37,156    Turkey 22,234    France 19,840    Argentina 1,553    Germany 52,970    Spain 3,932    Columbia 2,257    Italy 10,645    Mexico 3,836    Ukraine 20,050    Poland 23,242    Philippines 1,297    Malaysia 6,380    Netherlands 23,680    Peru 1,370    Thailand 6,855    Czechia 13,374    Canada 2,448    Romania 3,076    Chile 2,611    Serbia 3,219    Sweden 1,210    Portugal 2,398    Vietnam 10,223    Kazakhstan 1,272    Austria 14,212    Hungary 11,289    Greece 7,276    Georgia 4,278    Bulgaria 2,785    Belarus 1,844    Slovakia 7,418    Azerbaijan 2,124    Croatia 7,270    Bolivia 1,119    Ireland 4,646    Lithuania 1,847    Denmark 4,013    South Korea 3,034    Slovenia 3,662    Latvia 1,221    Laos 1,401    China 31    New Zealand 200    Australia 1,302   

Cancer drugs enter European market without evidence of survival or life quality benefit

Staff Writer |
Almost 57 percent of cancer drugs authorized by the European Medicines Agency (EMA) between 2003 and 2009 came onto the market without any clear evidence they improved the quality or quantity of patients' lives.

Article continues below






This is according to a study by King's College London.

A team led by researchers from King's College London and the London School of Economics and Political Science conducted the analysis.

They found that most cancer drugs were approved by the EMA using only surrogate measures which, although indicators, were not strong predictors of survival - whether living longer or feeling better.

"We evaluated the evidence base for all new drugs entering the market over a five year period and found that the majority came onto the market without clear evidence that they improved patients' survival or quality of life," said Dr Courtney Davis from King's College London.

When expensive drugs that lack robust evidence of clinical benefit were approved and reimbursed within publicly funded healthcare systems, individual patients may be harmed and public funds wasted, said Davis.

The team also found that even after a median follow-up of five years, 49 percent of the drugs still showed no quality or quantity of life benefit and of those that did, these benefits were judged to be clinically insignificant around 50 percent of the time.


What to read next

Second cancers deadlier for younger people
Many with breast cancer unnecessarily choose double mastectomy
Record 15.5 million Americans now surviving cancer